Abbott Laboratories hits 52-week low amid challenges

Abbott stock hit a 52-week low at $102.39, down 22.81% in a year. It remains on InvestingPro's Most Undervalued list and has paid dividends for 56 years. The Exact Sciences acquisition is expected to boost sales.

Abbott Laboratories stock recently hit a 52-week low at $102.39, reflecting a challenging year with a 22.81% decline over the past twelve months. This downturn is attributed to both broader market fluctuations and company-specific issues. Despite these challenges, InvestingPro data suggests Abbott may be undervalued, as it appears on the Most Undervalued list, indicating notable upside potential. The company has also demonstrated resilience by maintaining its dividend payments for 56 consecutive years, currently offering a 2.42% yield. In addition, Abbott completed its acquisition of Exact Sciences, enhancing its cancer screening and diagnostics capabilities. This strategic move is projected to add approximately $3 billion in incremental sales by 2026, though it may dilute adjusted earnings per share by $0.20 that year.